TrovaGene Inc. (TROV)

2.09
NASDAQ : Health Technology
Prev Close 1.63
Day Low/High 1.65 / 2.10
52 Wk Low/High 1.30 / 9.65
Avg Volume 91.60K
Exchange NASDAQ
Shares Outstanding 5.44M
Market Cap 8.87M
EPS -8.30
P/E Ratio 1.33
Div & Yield N.A. (N.A)

Latest News

ESMO Accepts Trovagene AML Clinical Trial Abstract For Oral Presentation

ESMO Accepts Trovagene AML Clinical Trial Abstract For Oral Presentation

- Acute Myeloid Leukemia (AML) clinical trial data to be presented in an oral presentation

Trovagene Commences Non-Deal Investor Roadshow

Trovagene Commences Non-Deal Investor Roadshow

Management team to meet with investment institutions, analysts and shareholders in NYC to provide an overview of the Company and its advancing clinical development of onvansertib

Trovagene Announces Initiation Of Enrollment For Phase 1b/2 Clinical Trial In KRAS-Mutated Colorectal Cancer At Leading Comprehensive Cancer Centers

Trovagene Announces Initiation Of Enrollment For Phase 1b/2 Clinical Trial In KRAS-Mutated Colorectal Cancer At Leading Comprehensive Cancer Centers

Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic Colorectal Cancer (mCRC)

Trovagene To Host Business Update Conference Call On June 7, 2019

Trovagene To Host Business Update Conference Call On June 7, 2019

Conference Call Begins at 11:00 am EDT

Trovagene Announces Research Collaboration With Nektar Therapeutics To Evaluate Efficacy Of The Combination Of Onvansertib And ONZEALD™ In Models Of Colorectal Cancer

Trovagene Announces Research Collaboration With Nektar Therapeutics To Evaluate Efficacy Of The Combination Of Onvansertib And ONZEALD™ In Models Of Colorectal Cancer

ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastases

Trovagene Announces Equity Investment Of $1.5 Million At Premium To Market Price From Institutional Investor, Lincoln Park Capital

Trovagene Announces Equity Investment Of $1.5 Million At Premium To Market Price From Institutional Investor, Lincoln Park Capital

Additional funding further extends runway for Trovagene to accelerate clinical development of onvansertib for the treatment of cancers where new therapeutic options are most needed

Trovagene Announces First Quarter 2019 Results And Highlights

Trovagene Announces First Quarter 2019 Results And Highlights

SAN DIEGO, May 7, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and...

Trovagene Announces Data Demonstrating Significant Synergy Of Onvansertib In Combination With Venetoclax In Cell Model Of Venetoclax-Resistant AML

Trovagene Announces Data Demonstrating Significant Synergy Of Onvansertib In Combination With Venetoclax In Cell Model Of Venetoclax-Resistant AML

Data provides support for clinical evaluation of onvansertib in combination with venetoclax in patients with difficult-to-treat relapsed or refractory acute myeloid leukemia (AML)

Trovagene Announces Update To Phase 1b/2 AML Trial Data Presented At AACR - Additional Patients Achieve Complete Response At Two Highest Dose Levels Of Onvansertib

Trovagene Announces Update To Phase 1b/2 AML Trial Data Presented At AACR - Additional Patients Achieve Complete Response At Two Highest Dose Levels Of Onvansertib

Complete response achieved in 3 of 6 (50%) evaluable patients at the highest doses (27mg/m2 and 40mg/m2) of onvansertib in combination with standard-of-care decitabine

Trovagene Announces $1.5 Million Equity Investment At Premium To Market From Institutional Investor, Lincoln Park Capital

Trovagene Announces $1.5 Million Equity Investment At Premium To Market From Institutional Investor, Lincoln Park Capital

Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants

Early Data From Phase 2 Trial Indicates Activity Of Onvansertib In Prostate Cancer Patients Showing Initial Resistance To Anti-Androgen Therapy

Early Data From Phase 2 Trial Indicates Activity Of Onvansertib In Prostate Cancer Patients Showing Initial Resistance To Anti-Androgen Therapy

Early PSA response observed when onvansertib is added to abiraterone (Zytiga®) in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint

Phase 1b/2 Dose Escalation Trial Of Onvansertib In Relapsed/Refractory AML Demonstrates Safety, Tolerability And Relative Durability With Complete Responses At Highest Dose Levels

Phase 1b/2 Dose Escalation Trial Of Onvansertib In Relapsed/Refractory AML Demonstrates Safety, Tolerability And Relative Durability With Complete Responses At Highest Dose Levels

Greatest anti-leukemic activity has been observed in the onvansertib + decitabine arm, with complete response in 2 of 4 (50%) of evaluable patients from the two highest dose levels

Trovagene Receives Approximately $3.0 Million From Exercise Of Warrants

Trovagene Receives Approximately $3.0 Million From Exercise Of Warrants

SAN DIEGO, March 13, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas...

Trovagene Regains Compliance With Nasdaq Listing Requirements

Trovagene Regains Compliance With Nasdaq Listing Requirements

SAN DIEGO, March 12, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas...

Trovagene Announces Fourth Quarter And Full-Year 2018 Results

Trovagene Announces Fourth Quarter And Full-Year 2018 Results

SAN DIEGO, March 6, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and...

Short Interest Expands By 14.2% For TROV

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 16.3% Higher For TROV

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 460,990 share increase in total short interest for TrovaGene Inc , to 3,292,918, an increase of 16.28% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TrovaGene (TROV) Is Today's Strong On High Volume Stock

TrovaGene (TROV) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc.

Short Interest Jumps 17.6% For TROV

Short Interest Jumps 17.6% For TROV

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 697,508 share increase in total short interest for TrovaGene Inc , to 4,657,297, an increase of 17.61% since 01/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Here’s Why TrovaGene (TROV) Stock is Soaring Today

Here’s Why TrovaGene (TROV) Stock is Soaring Today

TrovaGene (TROV) stock is spiking on Monday afternoon as the company enters an agreement with FedMed for access to cancer monitoring tests and services.

TrovaGene (TROV) Is Weak On High Volume Today

TrovaGene (TROV) Is Weak On High Volume Today

Trade-Ideas LLC identified TrovaGene (TROV) as a weak on high relative volume candidate

Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership

Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership

Trovagene (TROV) stock is climbing on heavy trading volume on Thursday after the company announced a partnership with America's Choice Provider Network.

Oversold Conditions For TrovaGene (TROV)

Oversold Conditions For TrovaGene (TROV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TROV: Insiders vs. Shorts

TROV: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 11/30/2015 settlement date, and TrovaGene Inc is one of the most shorted stocks of the Russell 3000, based on 8.86 "days to cover" versus the median component at 6.38. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

TheStreet Quant Rating: D- (Sell)